Treatment of prolactinomas

Annals of Medicine

Volumn 30, Issue 5, 1998, Pages 452-459

  Colao, Annamaria ^a   Annunziato, Lucio ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bromocriptine; Cabergoline; Dopamine agonists; Hyperprolactinaemia; Pituitary gland; Prolactin; Prolactinomas; Quinagolide

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; QUINAGOLIDE;

ARTICLE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; MENSTRUATION; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; TUMOR RECURRENCE; VERTIGO;

EID: 0031756127     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899809002486     Document Type: Article

References (78)

1. Vance ML, Thorner MO. Prolactin: hyperprolactinemic syndromes and management. In: DeGroot LJ, ed. Textbook of Endocrinology. 2nd edn. Philadelphia: WB Saunders; 1989: 408-18.
2. Costello RT. Subclinical adenoma of the pituitary gland. Am J Pathol 1936; 12: 205-16.
3. Burrow GN, Wortzman G, Rewcastle NB, et al. Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1980; 304: 156-8.
4. Schlechte J, Dolan K, Sherman B, Chapter F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68: 412-8.
5. Cunnah D, Besser M. Management of prolactinomas. Clin Endocrinol (Oxf) 1991; 34: 231-5.
6. Besser M. Criteria for medical as opposed to surgical treatment of prolactinomas. Acta Endocrinol 1993; 129 Suppl 1: 27-30.
7. Ross RJM, Grossman A, Bouloux P, Rees LH, Doniach I, Besser GM. The relationship between serum prolactin and immunocytochemical staining for prolactin in patients with pituitary macroadenomas. Clin Endocrinol (Oxf) 1985; 23: 227-35.B.
8. Aron DC, Tyrrell B, Wilson CB. Pituitary tumors: current concepts in diagnosis and management. World J Med 1995; 162: 340-52.
9. Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997; 82: 996-1000.
10. Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinaemia after selective adenomectomy in women with prolactinoma. N Engl J Med 1983; 309: 280-3.
11. Scanlon MF, Peters JR, Thomas JP, et al. Management of selected patients with hyperprolactinaemia by partial hypophysectomy. BMJ 1985; 291: 1547-53.
12. Thomson JA, Teasdale GM, Gordon D, McCruden DC, Davies DL. Treatment of presumed prolactinoma by transsphenoidal operation: early and late results. BMJ 1985; 291: 1550-3.
13. Rodman EF, Molitch ME, Kalmon PD, Biller BJ, Reichlin S. Long-term, follow-up of trans-sphenoidal selective adenomectomy for prolactinoma. JAMA 1984; 252: 921-4.
14. Scamoni C, Balzarini C, Crivclli G, Dorizzi A. Treatment and long-term follow-up results of prolactin secreting pituitary adenomas. J Neurosurg Sci 1991; 35: 9-16.
15. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 1992; 21: 877-901.
16. Molitch ME. Prolactinoma. In: Melmed S, ed. The Pituitary. Boston: Blackwell; 1995: 443-77.
17. Vance M, Evans W, Thorner M. Bromocriptine. Ann Intern Med 1984; 100: 78-91.
18. Turner TH, Cookson JC, Wass JAH, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonist. BMJ 1984; 289: 1101-3.
19. Rasmussen C, Brownell J, Berght T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinol 1991; 125: 170-6.
20. Merola B, Sarnacchiaro F, Colao A, et al. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. Biomed Pharmacother 1994; 48: 167-74.
21. Vilar L, Burke CW. Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine. Clin Endocrinol (Oxf) 1994; 41: 821-6.
22. Newman CB, Hurley AM, Kleinberg DL. Effect of CV 205-502 in hyperprolactinemic patients intolerant to bromocriptine. Clin Endocrinol (Oxf) 1989; 31: 391-400.
23. Merola B, Sarnacchiaro F, Colao A, et al. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994; 8: 1-7.
24. Webster J , Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-9.
25. Ciccarelli E, Ghigo E, Mazza E, et al. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia. J Endocrinol Invest 1987; 109: 79-82.
26. Grossman A, Ross R, Wass JAH, Besser GM. Depot bromocriptine for prolactinomas and acromegaly. Clin Endocrinol (Oxf) 1986; 24: 231-8.
27. Schettini G, Lombardi G, Merola B, et al. Rapid and long-lasting suppression on prolactin secretion and shrinkage of prolactinomas with improved tolerability after injection of long-action repeatable form of bromocriptine (Parlodel LAR). Clin Endocrinol (Oxf) 1990; 33: 161-9.
28. Kletzly OA, Wermesch M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil Steril 1989; 51: 269-72.
29. KIlbanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986; 315: 542-6.
30. Klibanski A, Neer RM, Beitins IZ, Ridgway C, Zarvas NT, Mc Arthur JW. Decreased bone density in amenorrheic women. N Engl J Med 1980; 303: 1511-4.
31. Jackson JA, Kleerekoper M, Parfitt M. Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism. Ann Intern Med 1986; 105: 543-5.
32. Greenspan SL, Oppenheim DS, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989; 110: 526-31.
33. Berezin M, Shimon I, Hadani M. Prolactinoma in 53 men: clinical characteristics and modes of treatment. J Endocrinol Invest 1995; 18: 436-41.
34. Di Somma C, Colao A, Di Sarno A, et al. Bone markers and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998; 83: 807-13.
35. Van't Verlaat JW, Croughs RJM, Brownell J. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502. Clin Endocrinol (Oxf) 1990; 33: 619-24.
36. Serri O, Beauregard H, Lesage J, et al. Long-term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 1990; 71: 682-7.
37. Crottaz B, Uske A, Reymond MJ, et al. CV 205-502 treatment of macroprolactinomas. J Endocrinol Invest 1991; 14: 757-62.
38. van der Lely AJ, Brownell J, Lamberts SWJ. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991; 72: 1136-41.
39. Biller BMK, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-13.
40. Ferrari C, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997; 46: 409-13.
41. Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997; 82: 3574-9.
42. Serri O. Progress in the management of hyperprolactinemia. N Engl J Med 1994; 331: 942-4.
43. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 221-35.
44. Colao A, Merola B, Sarnacchiaro F, et al. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Horm Res 1995; 44: 222-8.
45. Jenkins PJ, Jain A, Jones SL, Besser GM, Grossman AB. Oral prednisolohe supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy. Clin Endocrinol (Oxf) 1996; 45: 447-51.
46. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetski J, Kuhn JM. Effects of new dopaminergic agonist CV 205-502 on plasma PRL levels and tumor size in BRC-resistant prolactinomas. Clin Endocrinol (Oxf) 1991; 34: 25-9.
47. Razzaq R, O'Halloran DJ, Bearwell CG, Shalet SM. The effects of CV 205-502 in patients with hyperprolactinemia intolerant and/or resistant to bromocriptine. Horm Res 1993; 39: 218-22.
48. Brue T, Pellegrini I, Gunz G, et al. Effects of dopamine agonists CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992; 74: 577-84.
49. Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996; 134: 454-6.
50. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69: 500-9.
51. Scillitani A, Dicembrino F, Di Fazio P, et al. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxibenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J Clin Endocrinol Metab 1995; 80: 2523-5.
52. 2 receptor imaging in pituitary adenomas using Iodine-123-Epidepride and SPECT. J Nucl Med 1996; 37: 1931-7.
53. 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 1998; 83: 248-52.
54. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82: 876-83.
55. 3H]N-n-propylnorapomorphine. Eur J Pharmacol 1990; 187: 399-408.
56. 3H]CV 205-502. Brain Res 1988; 440: 123-32.
57. Webster J. A comparative review of the tolerability profiles of DA agonists in the treatment of hyperprolactinemia and inhibition of lactation. Drug Saf 1996; 14: 228-38.
58. Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995; 49: 255-79.
59. Ferrari C, Piscitelli G, Crosignani PG. Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum Reprod 1995; 10: 1647-52.
60. Turkalj I, Braun P, Krupp P. Surveillance of Bromocriptine in pregnancy. JAMA 1982; 247: 1589-91.
61. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993; 59: 671-3.
62. Ambrosi B, Gaggini M, Moriondo P, Faglia G. Prolactin and sexual function (letter). JAMA 1980; 244: 2608.
63. Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG. Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 1978; 299: 847-52.
64. Segal S, Yaffe H, Laufer N, Ben-David M. Male hyperprolactinemia: effects in fertility. Fertil Steril 1979; 32: 556-61.
65. Gonzales GF, Garcia-Hjarles M, Velasquez G. Hyperprolactinaemia and hyperserotoninaemia: their relationship to seminal quality. Andrologia 1992; 24: 95-100.
66. Park SK, Keenan MW, Selmanoff M. Graded hyperprolactinemia first suppresses LH pulse frequency and then pulse amplitude in castrated male rats. Neuroendocrinology 1993; 58: 448-53.
67. Bohnet HG, Dahlen HG, Wuttke W, Schneider HPG. Hyperprolactinemic anovulatory syndrome. J Clin Endocrinol Metab 1976; 42: 132-43.
68. Colao A, Merola B, Di Sarno A, et al. Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. Gynecol Endocrinol 1995; 9: 15-21.
69. Molitch ME, Rebar RW, Barsano CP. Effect of human prolactin administration on gonadotropin and thyrotropin secretion in normal men. J Endocrinol Invest 1993; 16: 559-64.
70. Rubin RT, Poland RE, Sobel I. Effects of prolactin and prolactin plus luteinizing hormone on plasma testosterone levels in normal adult men. J Clin Endocrinol Metab 1978; 47: 447-52.
71. Thorner MO, McNeilly AS, Hagan C, Besser GM. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. BMJ 1974; 2: 419-22.
72. Colao A, De Rosa M, Sarnacchiaro F, et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 1996; 135: 548-52.
73. De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138: 286-93.
74. Segal S, Yaffe H, Laufer N, Ben-David M. Male hyperprolactinemia: effects in fertility. Fertil Steril 1979; 32: 556-61.
75. Delgrange E, Donckier J. Gonadal dysfunction in males with prolactinoma: from functional modification to irreversible damage? Eur J Endocrinol 1997; 136: 630.
76. Faglia G. Should dopamine agonists treatment for prolactinomas be life-long? Clin Endocrinol (Oxf) 1991; 34: 173-4.
77. Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Lancet 1984; ii: 187-92.
78. Liuzzi A, Oppizzi G. Microprolactinomas: why requiem for surgery? J Endocrinol Invest 1996; 19: 196-8.